MERZ-AESTHETICS
Merz Aesthetics, a global leader in medical aesthetics, today announced that Radiesse® is celebrating ten million syringes shipped worldwide over almost twenty years. Radiesse® is a unique calcium hydroxylapatite (CaHA) injectable filler1 used for volumization, lifting and contouring, as well as skin rejuvenation by stimulating natural collagenogenesis.2,3 The product portfolio includes Radiesse® and Radiesse® Lidocaine delivering effective and natural-looking cosmetic results, distinguished by its established safety profile4 and high patient satisfaction.5
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005619/en/
“As we reflect on this milestone, we are proud of the fact that, Radiesse has proven to provide aesthetic practitioners with a unique treatment that they can administer confidently, while supporting their patients’ desired impact,” said Kristel Hectors, Head of Marketing EMEA, Merz Aesthetics. “With almost twenty years of scientific evidence and clinical experience, Radiesse is such a unique product and full of opportunities and possibilities. As we are looking ahead, we are excited for what’s to come over the next years for Radiesse.”
The milestone campaign launching under the tagline “The Power Used By Millions” reinforces the uniqueness of the product and its working mechanism. Informing health care professionals and educating patients on the uniqueness of Radiesse® , on its working mechanism and efficacy.
“Radiesse is my number one go to product because of its versatility. Radiesse plus for contouring, lifting, ligaments and volumizing. Classic Radiesse for classic indications like folds and of course hyperdiluted Radiesse for skin quality improvement,” said Jani van Loghem, MD Cosmetisch arts KNMG. “It is a biostimulatory product going beyond a hyaluronic acid: the collagen will be giving the patient the final result and it is a really nice message to the patient! That’s why I choose Radiesse.”
About Radiesse®
/Radiesse®
(+) Lidocaine
Radiesse®
is an injectable dermal filler that provides immediate volume and correction and continues to work by stimulating the body’s own natural collagen production. In addition, Radiesse activated the self-renewing potential within the skin to make the skin firm, elastic and strong. Radiesse can be tailored to individual requirements and skin condition.1,6-10
Radiesse® (+) Lidocaine injectable implant is an opaque, dermal filler that contains a small quantity of local anesthetic (lidocaine). In Europe, Radiesse® (+) Lidocaine is indicated for plastic / reconstructive procedures, including deep dermal and subdermal soft tissue augmentation of the facial area and for restoration and correction of facial volume loss. The presence of lidocaine is intended to reduce patient pain and to enhance comfort during treatment.1,6-10
Radiesse® / Radiesse® (+) Lidocaine is valued by doctors and patients around the world for its tolerability and safety profile. Radiesse received the CE mark for aesthetic use in Europe in 2004, with U.S. FDA approval following in 2006. In that time, Radiesse has been considered a leading minimally-invasive aesthetic treatment trusted by healthcare providers around the world. The product has been available on the market for more than fifteen years, with now 10 million syringes shipped worldwide and a clinically proven safety profile supported by more than 200 clinical studies and peer-reviewed publications.1,6-10
Radiesse is available in more than 70 countries worldwide.
About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. Radiesse® is a registered trademark of Merz North America, Inc.
1 RADIESSE Instructions for Use Nov. 2017. RADIESSE® Lidocaine Instructions for Use Jun.2018.
2 Berlin AL, et al. Dermatol Surg. 2008;34(suppl 1):S64-S67.
3 Moers-Carpi M, et al. Dermatol Surg. 2007;33(suppl 2):S144-S151.
4 Van Loghem JV, et al. J Clin Aesthet Dermatol. 2015:8(1)38-49.
5 Juhász MLW, Marmur ES, Dermatol Surg. 2018;44(8)1084-93.
6 Yutskovskaya Y, et al. J Drugs Dermatol. 2014;13(9):1047-52.
7 Yutskovskaya YA, Kogan EA. J Drugs Dermatol. 2017;16(1):68-74.
8 Schachter D, et al. J Drugs Dermatol. 2016 Aug 1; 15(8): 1005-10.
9 Sundaram H, et al. Dermatol Surg. 2010;36 (suppl 3):1859-1865.
10 Schachter Science Brief: Pain Control using the Injectable Dermal Filler Radiesse (+) for the correction of Nasolabial folds. Daniel Schachter, Vince Bertucci, Nowell Solish. POSTER PRESENTATION at 13th Anti-Aging Medicine World Congress (2015), Monaco, Monte Carlo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005619/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press release
At a $1.8 billion valuation, backed by L2 Point and Pure Storage, the company scales AI-first cloud storage to meet the explosive demands of modern data Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release
Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 14:00:00 CET | Press release
300mm SiC Technology, Enabling Scalable Platforms for AI Infrastructure, AR/VR, and Advanced Power DevicesAnnouncement highlights:Strategic Technology Milestone – Wolfspeed has produced a single crystal 300mm (12-inch) silicon carbide wafer, representing a major advancement in the evolution of silicon carbide technology and a critical enabler for emerging applications. Technology leadership for Next-Gen Applications – Backed by one of the industry’s largest and most foundational silicon carbide IP portfolios, with over 2,300 issued and pending patents worldwide, Wolfspeed is accelerating the commercialization of 300mm technology to power next-generation platforms including AI infrastructure, augmented reality/virtual reality (AR/VR) and advanced power devices. Strengthening U.S. Semiconductor Leadership & Supply Chain Resilience –The company’s vertically integrated supply chain, from crystal growth to advanced packaging, supports national goals around compound semiconductor independenc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom